Neos Therapeutics (NEOS) Announces Quarterly Earnings Results, Misses Estimates By $0.03 EPS
Neos Therapeutics (NASDAQ:NEOS) issued its quarterly earnings data on Friday. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.03), MarketWatch Earnings reports. The firm had revenue of $12.50 million for the quarter, compared to analysts’ expectations of $14.80 million. Neos Therapeutics had a negative net margin of 164.40% and a negative return on equity of 586.25%.
NASDAQ:NEOS traded up $0.01 during mid-day trading on Friday, hitting $2.59. 651,079 shares of the stock traded hands, compared to its average volume of 621,268. The stock has a market cap of $83.38 million, a P/E ratio of -0.97 and a beta of 0.44. Neos Therapeutics has a 12-month low of $2.27 and a 12-month high of $11.69.
Several equities analysts recently commented on the stock. Cantor Fitzgerald reaffirmed a “buy” rating and set a $20.00 price objective on shares of Neos Therapeutics in a research note on Friday. Wells Fargo & Co reduced their price objective on shares of Neos Therapeutics from $14.00 to $11.00 and set a “buy” rating for the company in a research note on Thursday, August 9th. Zacks Investment Research cut shares of Neos Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, July 25th. Finally, ValuEngine raised shares of Neos Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, September 18th. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Neos Therapeutics presently has an average rating of “Hold” and an average price target of $15.50.
Neos Therapeutics Company Profile
Neos Therapeutics, Inc, a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its product candidates are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms.
Read More: What is dollar cost averaging (DCA)?
Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.